Collectively, these data demonstrate that the combination therapy of vvDD-IL-9 and the anti-CTLA-4 antibody, but not the anti-GITR antibody, elicited potent systemic tumor-specific antitumor effects in a murine colon cancer model. Here, IL9 is linked to colonic neoplasm.